drugset / Trial / NCT01229332

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

NCT01229332

Phase 1/2 Completed 24 enrolled NeuroDerm Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be explored in subjects with PD and motor fluctuations.

Timeline

Start
2011-01
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbidopa Unknown Subcutaneous

Indications